Abstract:Targeting actionable mutations in oncogene‐driven cancers and the evolution of immuno‐oncology are the two prominent revolutions that have influenced cancer treatment paradigms and caused the emergence of precision oncology. However, intertumoral and intratumoral heterogeneity are the main challenges in both fields of precision cancer treatment. In other words, finding a universal marker or pathway in patients suffering from a particular type of cancer is challenging. Therefore, targeting a single hallmark or pathway with a single targeted therapeutic will not be efficient for fighting against tumor heterogeneity. Mesenchymal stem cells (MSCs) possess favorable characteristics for cellular therapy, including their hypoimmune nature, inherent tumor‐tropism property, straightforward isolation, and multilineage differentiation potential. MSCs can be loaded with various chemotherapeutics and oncolytic viruses. The combination of these intrinsic features with the possibility of genetic manipulation makes them a versatile tumor delivery vehicle that can be used for in vivo selective tumor delivery of various chemotherapeutic and biological therapeutics. MSCs can be used as biofactory for the local production of chemical or biological anticancer agents at the tumor site. MSC‐mediated immunotherapy could facilitate the sustained release of immunotherapeutic agents specifically at the tumor site, and allow for the achievement of therapeutic concentrations without the need for repetitive systemic administration of high therapeutic doses. Despite the enthusiasm evoked by preclinical studies that used MSC in various cancer therapy approaches, the translation of MSCs into clinical applications has faced serious challenges. This manuscript, with a critical viewpoint, reviewed the preclinical and clinical studies that have evaluated MSCs as a selective tumor delivery tool in various cancer therapy approaches, including gene therapy, immunotherapy, and chemotherapy. Then, the novel nanotechnology and bioengineering approaches that can improve the potency of MSC for tumor targeting and overcoming challenges related to their low localization at the tumor sites are discussed.

Signaling crosstalk between mesenchymal stem cells and tumor cells: Implications for tumor suppression or progression

New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons

Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways

Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches

Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity

Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy

Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells

Update on Mesenchymal Stem Cells: A Crucial Player in Cancer Immunotherapy

Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment

Mesenchymal Stem/stromal Cells in Cancer Therapy

Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines

Mesenchymal Stem Cells Inhibit Proliferation and Apoptosis of Tumor Cells: Impact on in Vivo Tumor Growth

The uncertain role of unmodified mesenchymal stem cells in tumor progression: what master switch?

Mesenchymal stem cell secretome and regenerative therapy after cancer

Dual impacts of mesenchymal stem cell-derived exosomes on cancer cells: unravelling complex interactions

Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment

Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle

Mesenchymal stromal cells as cancer promoters

Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells

Mesenchymal Stem Cells in Cancer Therapy

Mesenchymal stem/stromal cells: dedicator to maintain tumor homeostasis